Literature DB >> 34895835

MRI for Rectal Cancer: Staging, mrCRM, EMVI, Lymph Node Staging and Post-Treatment Response.

David D B Bates1, Maria El Homsi2, Kevin J Chang3, Neeraj Lalwani4, Natally Horvat2, Shannon P Sheedy5.   

Abstract

Rectal cancer is a relatively common malignancy in the United States. Magnetic resonance imaging (MRI) of rectal cancer has evolved tremendously in recent years, and has become a key component of baseline staging and treatment planning. In addition to assessing the primary tumor and locoregional lymph nodes, rectal MRI can be used to help with risk stratification by identifying high-risk features such as extramural vascular invasion and can assess treatment response for patients receiving neoadjuvant therapy. As the practice of rectal MRI continues to expand further into academic centers and private practices, standard MRI protocols, and reporting are critical. In addition, it is imperative that the radiologists reading these cases work closely with surgeons, medical oncologists, radiation oncologists, and pathologists to ensure we are providing the best possible care to patients. This review aims to provide a broad overview of the role of MRI for rectal cancer.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer staging; MRI; Radiology; Rectal cancer

Mesh:

Year:  2021        PMID: 34895835      PMCID: PMC8966586          DOI: 10.1016/j.clcc.2021.10.007

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


  77 in total

1.  Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Mustafa A Arain; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Linda Farkas; Ignacio Garrido-Laguna; Jean L Grem; Andrew Gunn; J Randolph Hecht; Sarah Hoffe; Joleen Hubbard; Steven Hunt; Kimberly L Johung; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Eric D Miller; Mary F Mulcahy; Steven Nurkin; Michael J Overman; Aparna Parikh; Hitendra Patel; Katrina Pedersen; Leonard Saltz; Charles Schneider; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Kristina M Gregory; Lisa A Gurski
Journal:  J Natl Compr Canc Netw       Date:  2021-03-02       Impact factor: 11.908

Review 2.  Prognostic factors after surgery for locally recurrent rectal cancer: an overview.

Authors:  M Caricato; D Borzomati; F Ausania; S Valeri; A Rosignoli; R Coppola
Journal:  Eur J Surg Oncol       Date:  2005-12-27       Impact factor: 4.424

Review 3.  Extramural venous invasion in rectal cancer: overview of imaging, histopathology, and clinical implications.

Authors:  Hamideh Ale Ali; Richard Kirsch; Suzan Razaz; Aaditeya Jhaveri; Seng Thipphavong; Erin D Kennedy; Kartik S Jhaveri
Journal:  Abdom Radiol (NY)       Date:  2019-01

Review 4.  MRI of Rectal Cancer: Tumor Staging, Imaging Techniques, and Management.

Authors:  Natally Horvat; Camila Carlos Tavares Rocha; Brunna Clemente Oliveira; Iva Petkovska; Marc J Gollub
Journal:  Radiographics       Date:  2019-02-15       Impact factor: 5.333

Review 5.  Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis.

Authors:  Marije P van der Paardt; Marjolein B Zagers; Regina G H Beets-Tan; Jaap Stoker; Shandra Bipat
Journal:  Radiology       Date:  2013-06-25       Impact factor: 11.105

6.  Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience.

Authors:  Uday B Patel; Fiona Taylor; Lennart Blomqvist; Christopher George; Hywel Evans; Paris Tekkis; Philip Quirke; David Sebag-Montefiore; Brendan Moran; Richard Heald; Ashley Guthrie; Nicola Bees; Ian Swift; Kjell Pennert; Gina Brown
Journal:  J Clin Oncol       Date:  2011-08-29       Impact factor: 44.544

7.  Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer.

Authors:  Uday Bharat Patel; Gina Brown; Harm Rutten; Nicholas West; David Sebag-Montefiore; Robert Glynne-Jones; Eric Rullier; Marc Peeters; Eric Van Cutsem; Sergio Ricci; Cornelius Van de Velde; Pennert Kjell; Philip Quirke
Journal:  Ann Surg Oncol       Date:  2012-04-24       Impact factor: 5.344

8.  Patients with low rectal cancer treated by abdominoperineal excision have worse tumors and higher involved margin rates compared with patients treated by anterior resection.

Authors:  Oliver C Shihab; Gina Brown; Ian R Daniels; Richard J Heald; Philip Quirke; Brendan J Moran
Journal:  Dis Colon Rectum       Date:  2010-01       Impact factor: 4.585

Review 9.  Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting.

Authors:  Regina G H Beets-Tan; Doenja M J Lambregts; Monique Maas; Shandra Bipat; Brunella Barbaro; Luís Curvo-Semedo; Helen M Fenlon; Marc J Gollub; Sofia Gourtsoyianni; Steve Halligan; Christine Hoeffel; Seung Ho Kim; Andrea Laghi; Andrea Maier; Søren R Rafaelsen; Jaap Stoker; Stuart A Taylor; Michael R Torkzad; Lennart Blomqvist
Journal:  Eur Radiol       Date:  2017-10-17       Impact factor: 5.315

10.  Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.

Authors:  David Sebag-Montefiore; Richard J Stephens; Robert Steele; John Monson; Robert Grieve; Subhash Khanna; Phil Quirke; Jean Couture; Catherine de Metz; Arthur Sun Myint; Eric Bessell; Gareth Griffiths; Lindsay C Thompson; Mahesh Parmar
Journal:  Lancet       Date:  2009-03-07       Impact factor: 79.321

View more
  1 in total

1.  Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).

Authors:  K van den Berg; D P Schaap; E L K Voogt; T E Buffart; H M W Verheul; J W B de Groot; C Verhoef; J Melenhorst; J M L Roodhart; J H W de Wilt; H L van Westreenen; A G J Aalbers; M van 't Veer; C A M Marijnen; J Vincent; L H J Simkens; N A J B Peters; M Berbée; I M Werter; P Snaebjornsson; H M U Peulen; I G van Lijnschoten; M J Roef; G A P Nieuwenhuijzen; J G Bloemen; J M W E Willems; G J M Creemers; J Nederend; H J T Rutten; J W A Burger
Journal:  BMC Cancer       Date:  2022-09-06       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.